Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

REPOTRECTINIB vs REVEFENACIN: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

REPOTRECTINIB vs REVEFENACIN: Safety Overview

Metric REPOTRECTINIB REVEFENACIN
Total FAERS Reports 187 280
Deaths Reported 27 11
Death Rate 14.4% 3.9%
Hospitalizations 48 23
Average Patient Age 60.8 yrs 72.4 yrs
% Female Patients 61.1% 59.1%
FDA Approval Date Jun 11, 2024 Nov 9, 2018
Manufacturer E.R. Squibb & Sons, L.L.C. Viatris Specialty LLC
Route ORAL RESPIRATORY (INHALATION)
Marketing Status Prescription Prescription